IPO - Profile

NexImmune, Inc.

Health Care > Major Pharmaceuticals



We are a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. Currently, we have two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

The backbone of our approach is our proprietary Artificial Immune Modulation, or AIMTM, nanoparticle technology platform. The More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 6,470,000 Positive High 53.52%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 11 Feb, 2021

Offer 12 Feb, 2021

Look Ahead

Lock Up Expiry Aug 12, 2021

IPO Terms

Offer Price $17.00
Offer Size 6M

Market Sentiments

Stock Price